Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

Inclusion Criteria: * age ≥ 65 years; * histologically confirmed adenocarcinoma of the prostate; * metastatic disease; * unresponsive or refractory to hormonal therapy, as defined by at least 1 of the following criteria: progression of bidimensionally measurable disease; progression of evaluable but not measurable disease (bone scan); at least 2 consecutive rises in PSA at least 1 week apart; * patients must have serum testosterone levels \< 50 ng/mL at time of study entry. For patients who are medically castrated, lutenizing hormone releasing hormone analog must continue to maintain testicular suppression; * prior nonsteroidal antiandrogens (flutamide, ketoconazole, bicalutamide, or nilutamide) allowed if disease progression occurred. No evidence of response after antiandrogen withdrawal within 4 weeks for patients treated with flutamide, ketoconazole, nilutamide and 6 weeks for patients treated with bicalutamide; * chemotherapy naïve; * full recovery from the effects of any prior surgery or radiation therapy. At least 4 weeks since any radiation therapy; * ECOG performance status 0-2; * adequate kidney, liver, and bone marrow functions; * signed study-specific informed consent form. Exclusion Criteria: * Concurrent chemotherapy or immunotherapy; * Patients who have received an investigational drug within 4 weeks of registration; * Prior or concurrent malignancies (other than surgically treated carcinoma in situ of the cervix and squamous or basal cell carcinoma of the skin) within the preceding five years; * Serious medical or psychiatric illness which would prevent informed consent; * Life expectancy \< 3 months; * Active uncontrolled bacterial, viral, or fungal infection until these conditions are corrected or controlled; * Known hypersensitivity to study drug or to other drugs formulated with polysorbate 80.